Chinese Journal of Clinical Anatomy >
The change of PC12 cells and the expression of CXCR4/CXCL12 under the 6-OHDA’s injury
Received date: 2013-12-16
Online published: 2014-12-04
Objective To study the change of PC12 cells and the expression of CXCR4 and CXCL12 under the 6-OHDA’s injury. Methods PC12 cells were treated with concentration gradient of 6-OHDA.The the morphological change of PC12 cells was observed with light microscope, then MTT assay was used to detect the viability of PC12 cells treated with 6-OHDA . And the expression of CXCL12 and CXCR4 was detected in different 6-OHDA concentrations with indirect immunofluorescence technique. Results With the increase of the concentration of 6-OHDA, the survival rate of PC12 cells decreased gradually. The number of the PC12 cells decreased, with the axon becoming shorter or disappearing. The results of indirect immunofluorescence technique showed that the expression of CXCR4 and CXCL12 increased with the amount of 6-OHDA. Conclusion The increase of the concentration of 6-OHDA leads to the apoptosis of the PC12 cells and the increase of the expression of CXCR4 and CXCL12.
WANG Hui , BAO Li-Hua , LI Chao , LI Gui-Bao , TUN Qi , SHU De-Xiao , TUN Jin-Chao , LIU Hai-Chi , ZHANG Jing , SUN Jin-Gao . The change of PC12 cells and the expression of CXCR4/CXCL12 under the 6-OHDA’s injury[J]. Chinese Journal of Clinical Anatomy, 2014 , 32(6) : 680 -684 . DOI: 10.13418/j.issn.1001-165x.2014
[1] Lunn JS, Sakowski SA, Hur J, et al. Stem cell technology for neurodegenerative diseases
[J]. Ann Neurol, 2011, 70(3): 353-361.
[2] Soykan I, Lin Z, Bennett JP, et al. Gastric myoelectrical activity in patients with Parkinson's disease (Evidence of a Primary Gastric Abnormality)
[J]. Dig Dis Sci, 1999, 44(5): 927-931.
[3] Cersosimo MG, Benarroch EE. Pathological correlates of gastrointes- tinal dysfunction in Parkinson's disease
[J]. Neurobiol Dis, 2012, 46(3): 559-564.
[4] Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease
[J]. Parkinsonism Relat Disord, 2011,17(1): 10-15.
[5] Salawu FK, Danburam A, Olokoba AB. Non-motor symptoms of Parkinson's disease: diagnosis and management
[J]. Niger J Med, 2010, 19(2):126-131.
[6] Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction
[J]. Circ J, 2010, 74(3): 418-423.
[7] Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-speci?c antibodies
[J]. Leukemia, 2004, 18(1): 1-10.
[8] ernández-López C, Varas A, Sacedón R, et al. The CXCL12/CXCR4 pair in aged human thymus
[J]. Neuroimmunomodulation, 2010,17(3): 217-220.
[9] Gassmann P, Haier J, Schlüter K, et al. CXCR4 regulates tumor cell extravasation in vivo
[J]. Neoplasia, 2009, 11(7): 651-661.
[10]Shimoji M, Pagan F, Healton EB, et al. CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease
[J]. Neurotox Res, 2009,16(3): 318-328.
[11]Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room
[J]? Biomed Pharmacother, 2008, 62(4):236-249.
[12]Jenner P. Oxidative stress and Parkinson's disease
[J]. Handb Clin Neurol, 2007, 83:507-520.
[13]Cuadrado A, Rojo A I. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections
[J]. Curr Pharm Des, 2008, 14(5):429-442.
[14]Chao Y, Wong SC, Tan EK. Evidence of inflammatory system involvement in Parkinson's disease
[J]. Biomed Res Int, 2014:308654.
[15]Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with
[11C](R)-PK11195 PET in idiopathic Parkinson's disease
[J]. Neurobiol Dis, 2006, 21(2):404-412.
[16]Tran PB, Ren D, Veldhouse TJ, et al. Chemokine receptors are expressed widely by embryonic and adult neural progenitor cells
[J]. J Neurosci Res, 2004, 76(1): 20-34.
[17]Carbajal KS, Schaumburg C, Strieter R, et al. Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis
[J]. Proc Nati Acad Sci U S A, 2010, 107(24): 11068-11073.
[18]McCandless EE, Budde M, Lees JR, et al. IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis
[J]. J Immunol, 2009, 183(1):613-620.
[19]McCandless EE, Piccio L, Woerner BM, et al. Pathological expression of CXCL12 at the blood -brain barrier correlates with severity of multiple sclerosis
[J]. Am J Pathol , 2008, 172(3):799-808.
[20]Mocchetti I, Bachis A, Masliah E. Chemokine receptors and neurotrophic factors: potential therapy against aids dementia
[J]? J Neurosci Res, 2008, 86(2):243-255.
[21]Robin AM, Zhang ZG, Wang L, et al. Stromal cell derived factor-1 alpha mediates neural progenitor cell motility after focal cerebral ischemia
[J] . J Cereb BloodFlow Metab, 2006, 26(1):125- 134.
[22]Bachis A, Mocchetti I. The chemokine receptor CXCR4 and not the N-methyl-D-aspartate receptor mediates gp120 neurotoxicity in cerebellar granule cells
[J]. J Neurosci Res, 2004, 75(1):75-82.
[23]Corasaniti MT , Piccirilli S, Pao letti A, et al. Evidence that the HIV-1 coat protein gp120 causes neuronal apoptosis in the neocortex of rat via a mechanism involving CXCR4 chemokine receptor
[J]. Neurosci Lett, 2001, 312(2): 67- 70.
/
| 〈 |
|
〉 |
